How safe are very low LDL cholesterol levels?
Sarkis B Baghdasarian and Paul D Thompson*
Correspondence *Hartford Hospital, 80 Seymour Street, PO Box 5037, Hartford, CT 5037, USA
Email pthomps@harthosp.org
This article has no abstract so we have provided the first paragraph of the full text.
The PROVE IT-TIMI 22 trial randomly assigned patients with ACS to treatment with either 80 mg atorvastatin daily or 40 mg pravastatin daily.1 The composite endpoint was reduced by 16% in the atorvastatin group over an average of 24 months' follow-up; however, this approach of intensive statin treatment has raised concerns about the safety of achieving markedly low LDL cholesterol levels.2
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
